At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP).
Analysis of Clinical Characteristics and Treatment Trends in Hospitalized Patients with Cardiovascular Diseases in the Baise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback